Show simple item record

dc.contributor.authorKongbunkiat, Kannikar
dc.contributor.authorWilson, Duncan
dc.contributor.authorKasemsap, Narongrit
dc.contributor.authorTiamkao, Somsak
dc.contributor.authorJichi, Fatima
dc.contributor.authorPalumbo, Vanessa
dc.contributor.authorHill, Michael D.
dc.contributor.authorBuchan, Alastair M.
dc.contributor.authorJung, Simon
dc.contributor.authorMattle, Heinrich P.
dc.contributor.authorHenninger, Nils
dc.contributor.authorWerring, David J.
dc.date2022-08-11T08:10:30.000
dc.date.accessioned2022-08-23T17:11:11Z
dc.date.available2022-08-23T17:11:11Z
dc.date.issued2017-02-14
dc.date.submitted2017-03-29
dc.identifier.citationNeurology. 2017 Feb 14;88(7):638-645. doi: 10.1212/WNL.0000000000003605. Epub Jan 27 2017. <a href="https://doi.org/10.1212/WNL.0000000000003605">Link to article on publisher's site</a>
dc.identifier.issn0028-3878 (Linking)
dc.identifier.doi10.1212/WNL.0000000000003605
dc.identifier.pmid28130468
dc.identifier.urihttp://hdl.handle.net/20.500.14038/46218
dc.description<p>Co-author Nils Henninger is a doctoral student in the Millennium PhD Program (MPP) in the Graduate School of Biomedical Sciences (GSBS) at UMass Medical School.</p>
dc.description.abstractOBJECTIVE: To perform a systematic review and pooled meta-analysis of published studies to assess whether the presence of leukoaraiosis on neuroimaging before treatment with thrombolysis (IV or intra-arterial) is associated with an increased risk of symptomatic intracerebral hemorrhage (sICH) or poor functional outcome. METHODS: We included studies of patients with acute ischemic stroke, treated with IV or intra-arterial thrombolysis, which assessed functional outcome (3-month modified Rankin Scale [mRS]) or sICH in relation to leukoaraiosis on pretreatment neuroimaging (CT or MRI). We used random-effects models to calculate pooled relative risks (RR) of sICH and poor functional outcome (mRS > /= 2) for any vs no leukoaraiosis (using any rating scale) and for no to mild vs moderate to severe leukoaraiosis (using the Van Swieten or Fazekas Schmidt scale). RESULTS: We identified 15 studies (total n = 6,967). For sICH outcome, the RR was 1.65 (n = 5,551; 95% confidence interval [CI] 1.26-2.16, p = 0.001) with an absolute risk (AR) increase of 2.5% for any leukoaraiosis vs none. The RR was 2.4 (n = 4,192; 95% CI 1.83-3.14, p = 0.001) with an AR increase of 6.2% for moderate to severe vs no to mild leukoaraiosis. For poor functional outcome; the RR was 1.30 (n = 3,401; 95% CI 1.19-1.42, p = 0.001) with an AR increase of 15.4% for any leukoaraiosis vs none. The RR was 1.31 (n = 3,659; 95% CI 1.22-1.42, p = 0.001) with an AR increase of 17.5% for moderate to severe vs no to mild leukoaraiosis. No statistical heterogeneity was noted for any of the analyses. CONCLUSIONS: Leukoaraiosis presence and severity are consistently associated with an increased risk of sICH and poor functional outcome after IV or intra-arterial thrombolysis for acute ischemic stroke.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=28130468&dopt=Abstract">Link to Article in PubMed</a>
dc.rightsCopyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectNervous System Diseases
dc.subjectNeurology
dc.subjectPsychiatry
dc.titleLeukoaraiosis, intracerebral hemorrhage, and functional outcome after acute stroke thrombolysis
dc.typeJournal Article
dc.source.journaltitleNeurology
dc.source.volume88
dc.source.issue7
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1759&amp;context=psych_pp&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/psych_pp/755
dc.identifier.contextkey9942011
refterms.dateFOA2022-08-23T17:11:11Z
html.description.abstract<p>OBJECTIVE: To perform a systematic review and pooled meta-analysis of published studies to assess whether the presence of leukoaraiosis on neuroimaging before treatment with thrombolysis (IV or intra-arterial) is associated with an increased risk of symptomatic intracerebral hemorrhage (sICH) or poor functional outcome.</p> <p>METHODS: We included studies of patients with acute ischemic stroke, treated with IV or intra-arterial thrombolysis, which assessed functional outcome (3-month modified Rankin Scale [mRS]) or sICH in relation to leukoaraiosis on pretreatment neuroimaging (CT or MRI). We used random-effects models to calculate pooled relative risks (RR) of sICH and poor functional outcome (mRS > /= 2) for any vs no leukoaraiosis (using any rating scale) and for no to mild vs moderate to severe leukoaraiosis (using the Van Swieten or Fazekas Schmidt scale).</p> <p>RESULTS: We identified 15 studies (total n = 6,967). For sICH outcome, the RR was 1.65 (n = 5,551; 95% confidence interval [CI] 1.26-2.16, p = 0.001) with an absolute risk (AR) increase of 2.5% for any leukoaraiosis vs none. The RR was 2.4 (n = 4,192; 95% CI 1.83-3.14, p = 0.001) with an AR increase of 6.2% for moderate to severe vs no to mild leukoaraiosis. For poor functional outcome; the RR was 1.30 (n = 3,401; 95% CI 1.19-1.42, p = 0.001) with an AR increase of 15.4% for any leukoaraiosis vs none. The RR was 1.31 (n = 3,659; 95% CI 1.22-1.42, p = 0.001) with an AR increase of 17.5% for moderate to severe vs no to mild leukoaraiosis. No statistical heterogeneity was noted for any of the analyses.</p> <p>CONCLUSIONS: Leukoaraiosis presence and severity are consistently associated with an increased risk of sICH and poor functional outcome after IV or intra-arterial thrombolysis for acute ischemic stroke.</p>
dc.identifier.submissionpathpsych_pp/755
dc.contributor.departmentMorningside Graduate School of Biomedical Sciences
dc.contributor.departmentPsychiatry
dc.contributor.departmentNeurology
dc.source.pages638-645
dc.contributor.studentNils Henninger
dc.description.thesisprogramMillennium PhD


Files in this item

Thumbnail
Name:
NEUROLOGY2016743310.pdf
Size:
696.6Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Except where otherwise noted, this item's license is described as Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.